Transaction summary
- Target
- Edgewise Therapeutics' Muscular Dystrophy Business
- Acquirer
- Servier
- Seller
- Edgewise Therapeutics
- Announced
- -
- Completed
- 2026-07-13
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-27
- Latest update
- 2026-08-03
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Locally publishable after independent verification and publication guards.
Source summary
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire
ConfirmedA PR Newswire release states that Servier completed its acquisition of Edgewise Therapeutics' muscular dystrophy business.
Open sourceContinue your research
Related transaction comps
Biotech
Dersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → Biotech4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → BiotechCelgene acquired by Bristol-Myers Squibb
2019-01-03 · Confirmed
View transaction → BiotechITM Isotope Technologies Munich SE acquired by Telix Pharmaceuticals Limited
2026-09-20 · Confirmed
View transaction →